Vol.

No.

February 06, 2026Feb 06, 2026

DOWNLOAD THE PDF

On Day 2 as director of NYU Perlmutter, Anirban Maitra talks about the advantages of running a matrix cancer center

Cover Story

Conversation with The Cancer Letter

On Day 2 as director of NYU Perlmutter, Anirban Maitra talks about the advantages of running a matrix cancer center

By Paul Goldberg

Last summer, Anirban Maitra, a pathologist specializing in pancreatic cancer, joined the NYU Langone Health Laura and Isaac Perlmutter Cancer Center to co-lead its Gastrointestinal Cancer Center.

NCI

Letai: NCAB’s ad hoc working group plays major role in advising NCI on extramural research
The group replaced the NCI Board of Scientific Advisors

By Claire Marie Porter

Black History Month Podcast

Black History Month: Otis Brawley shares how lessons learned in West Side Detroit shape his stance on cancer prevention
“Trying to realize how good we actually could be if our system were truly efficient is what Otis is all about”

By Robert A. Winn, Otis W. Brawley and Preston Willett

Guest Editorial

The National Highway Traffic Safety Administration has a profound, albeit not immediately obvious, impact on cancer

By Ken Kobayashi and Joan H. Schiller

Cancer Policy

NIH’s Bhattacharya acknowledges absence of causal link between vaccines and autism

White House launches TrumpRx website

“Basic Experimental Studies Involving Humans” no longer classified as clinical trials at NIH in an effort to reduce administrative burden

FDA debuts precheck manufacturing program to boost domestic drug development

In Brief

Alex Khariton named COO and SVP for cancer services at Fox Chase

George Coukos launches Ludwig Laboratory for Cell Therapy at Weill Cornell

MSK launches MSK Care Partners to expand access to cancer care

Sylvester opens Griffin Cancer Research Building

ASTRO launches national radiopharmaceutical therapy training centers

Neuroendocrine Tumor Research Foundation names 13 grant recipients

University of York awarded £2.5 million to study blood cancers in the U.K.

Clinical Roundup

NCCN updates guidelines recognizing MammaPrint to guide personalized anthracycline use in HR+/HER2- early‑stage breast cancer

Neoadjuvant pembrolizumab helps shrink tumors in patients with desmoplastic melanoma

Oxybutynin reduces hot flashes during prostate cancer treatment, randomized study finds

Oral cancer pain and opioid tolerance share underlying process, study finds

Researchers build best practice framework to boost racial and cultural diversity in biospecimen research

Researchers create blueprint for designing CD8 killer T cells to kill cancer cells

Drugs & Targets

FDA issues a boxed warning for capecitabine and fluorouracil on risks associated with DPD deficiency

NCI Trials

NCI Trials for February 2026

The National Cancer Institute approved the following clinical research studies last month.

PREVIOUS ISSUE

NEXT ISSUE

Recent Issues

Volume 52 | Issue 08 - February 27, 2026